Combined measles, mumps, rubella and varicella vaccine (MMRV) has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Combined measles, mumps, rubella and varicella vaccine  (MMRV) studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
208136/019 (MeMuRu-OKA-019 III A phase III, open, randomized, controlled study to evaluate the immunogenicity and safety of one dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children of 4 to 6 years of age previously primed with one dose of measles-mumps-rubella vaccine (GlaxoSmithKline Biologicals’ Priorix™ or Merck & Co.’s M-M-R II™). MMR (Priorix™): measles-mumps-rubella vaccine; M-M-R II™: measles-mumps-rubella vaccine.
103388 (MMRV-042) & 104690 (MMVR-045) III A phase IIIb, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children during the second year of life following a 4-week and a 12-month interval between two doses. MeMuRu-OKA (MMRV): GlaxoSmithKline (GSK) Biologicals’ measles-mumps-rubella-varicella vaccine.
104020 (MeMuRu-OKA-043) III A phase III, partially blind, randomized, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), when given as a two-dose schedule to healthy children in their second year of life. MeMuRu-OKA: GSK Biologicals' combined measles, mumps, rubella and varicella vaccine.
104389 (MeMuRu-OKA/044) III A phase III, blinded, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life. MeMuRu-OKA: GlaxoSmithKline (GSK) Biologicals' combined measles, mumps, rubella and varicella vaccine.
106670 (MeMuRu-OKA 048) III Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) to healthy children aged 11 to 21 months. MeMuRu-OKA: GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV).
208136/007 (MeMuRu-OKA-007) III A phase III, randomised, controlled primary vaccination study to assess the consistency of 3 production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) in terms of immunogenicity and safety, compared to the administration of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix™) and varicella vaccine (Varilrix™) (either concomitantly or 6 weeks apart) in healthy children in their second year of life.
208136/013 (MeMuRu-OKA-013) III A phase III, open, randomized, clinical study in healthy children 12 to 24 months of age, to assess the immunogenicity and safety of one dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), co-administered with a booster dose of the GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine (Infanrix-HeXa™), compared to MeMuRu-OKA administered alone and compared to GSK Biologicals’ Infanrix-HeXa™ vaccine administered alone. DTPa-HBV-IPV/Hib (Infanrix-HeXa™): Diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine.
208136/014 (MeMuRu-OKA-014) III A phase III, open, randomised, controlled multicentre study to evaluate the immunogenicity and safety of one dose of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children 4 to 6 years of age previously primed with one dose of measles-mumps-rubella vaccine (either Priorix™ or M-M-R II™) in their second year of life and presumed seronegative for varicella. MMR (Priorix™): GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine; M-M-R II: commercially available measles-mumps-rubella vaccine.
208136/016 (MeMuRu-OKA-016) III A phase III, single-blind, randomised, multicentre study to assess the immunogenicity and safety of two lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine (MeMuRu-OKA), at two different titres, given as a single injection to healthy children in their second year of life with GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) as a control group. MMR (Priorix™): Measles-mumps-rubella vaccine.
208136/018 (MeMuRu-OKA-018) III A phase III, open, randomized, controlled, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) compared to concomitant administrations of GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) and varicella vaccine (Varilrix™) administered as a two-dose vaccination to healthy infants in their 9th and 12th months of life.
208136/022 (MeMuRu-OKA-022) III A phase III, open, randomised, controlled multicentre study to evaluate the immunogenicity and safety of one dose of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) compared to concomitant administrations of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix™) and varicella vaccine (Varilrix™) given to healthy infants at 12 to 15 months of age primed with a single dose of a monovalent measles vaccine at 9 months of age.
208136/038 (MeMuRu-OKA-038) III A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix™) and varicella vaccine (Varilrix™). MMR (Priorix™): measles-mumps-rubella vaccine.
208136/039 (MeMuRu-OKA-039) III A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix®) and varicella vaccine (Varilrix®). Priorix®: GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (MMR) Varilrix®: GlaxoSmithKline Biologicals’ varicella vaccine (V).
208136/040 (MeMuRu-OKA-040) III A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix®) and varicella vaccine (Varilrix®). Priorix®: GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (MMR) Varilrix®: GlaxoSmithKline Biologicals’ varicella vaccine (V)
208136/041 (MeMuRu-OKA-041) III A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (Priorix®) and varicella vaccine (Varilrix®). Priorix®: GlaxoSmithKline Biologicals’ measles-mumps-rubella vaccine (MMR) Varilrix®: GlaxoSmithKline Biologicals’ varicella vaccine (V)
105908 (MeMuRu-OKA-046) II A phase II, open, randomized, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) co-administered in separate injections with GSK Biologicals’ varicella (Varilrix™) vaccine when given in healthy children who previously received a first dose of an MMR vaccine. MeMuRu-OKA (MMRV): GlaxoSmithKline (GSK) Biologicals’ measles-mumps-rubella-varicella candidate vaccine. Priorix™ (MMR): GSK Biologicals’ licensed combined measles-mumps-rubella vaccine. Varilrix™ (VAR): GSK Biologicals’ licensed varicella vaccine.
105909 (MeMuRu-OKA-047) II A phase II, open, randomized, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline’s (GSK) Biologicals’ measles-mumps-rubella-varicella candidate vaccine (MeMuRu-OKA) and GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) co-administered in separate injections with GSK Biologicals’ varicella vaccine (Varilrix™) when given in healthy children who previously received a first dose of an MMR vaccine and one dose of a varicella vaccine. MeMuRu-OKA (MMRV): GSK Biologicals’ measles-mumps-rubella-varicella (Oka strain) candidate vaccine. Priorix™ (MMR): GSK Biologicals’ licensed combined measles-mumps-rubella vaccine. Varilrix™ (VAR): GSK Biologicals’ licensed varicella vaccine.
208136/006 (MeMuRu-OKA-006) II A phase II, open, randomized, multicentre study evaluating in healthy children 12-24 months of age the safety and immunogenicity of GlaxoSmithKline Biologicals' combined Measles-Mumps-Rubella-Varicella vaccine (MeMuRu-OKA), compared to GlaxoSmithKline Biologicals' Varicella (Varilrix™) and Measles-Mumps-Rubella (Priorix™) vaccines administered as separate injections. MeMuRu-OKA: GlaxoSmithKline (GSK) Biologicals’ combined Measles-Mumps-Rubella-Varicella vaccine Varilrix™: GSK Biologicals’ Varicella vaccine Priorix™: GSK Biologicals’ Measles-Mumps-Rubella vaccine (MMR)
208136/017 (MeMuRu-OKA-017) II A phase II, open, case-controlled clinical study to assess the immunogenicity, reactogenicity and safety of a 2nd dose of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine given in healthy children of 5 to 6 years of age.